WACKER Posts Higher Sales for 2018, with EBITDA Below Previous Year Due to As-Yet
Outstanding Insurance Compensation
WACKER Strengthens Portfolio of Specialties by Expanding its Production Capacities
for Silicone Rubber Worldwide
WACKER's Newly Acquired Pharmaceutical Protein Production SynCo Bio Partners B.V.
in the Netherlands is Now Wacker Biotech B.V.
EBITDA for 2018 expected to be below guidance due to still outstanding insurance compensation
ADJUSTED EBITDA IN Q2 2016 EXPECTED TO EXCEED CURRENT MARKET ESTIMATES
PLACEMENT PRICE FOR SILTRONIC AG SHARE SET AT EUR 30 PER SHARE